Massive Rotator Cuff Arthropathy with Glenohumeral Arthritis

Abstract

Rotator cuff tear arthropathy with glenohumeral osteoarthritis (CTA) represents the classic indication for reverse shoulder arthroplasty (RSA). Historically, this disease process was frustrating and difficult to treat, with patients hoping to achieve what Charles Neer described as “limited goals” for functional outcomes. The introduction of RSA has revolutionized the treatment of CTA providing reliable and reproducible improvements in pain, function, and range of motion (ROM). The limitations of RSA relate to concerns over complication rates and implant longevity. As a relatively new procedure, a greater understanding of the changes in shoulder kinematics, biomechanical effects of the reverse articulation, surgical techniques, and implant designs will continue to improve. These changes have already led to improvements in patient outcomes and complication rates. This trend will likely continue. As more long-term data become available, questions regarding implant longevity will be clarified.